# TransformativeMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transformativemed

- Industry: Software
- Headquarters: Seattle, US
- Website: www.transformativemed.com
- Total disclosed funding: $5.8M
- Latest round: Series A (May 7, 2019)
- Investors on record: 1

## About

TransformativeMed, Inc. offers innovative clinical solutions focused on enhancing glycemic management through its CORES Platform, designed to improve workflow efficiency and patient care in healthcare settings.TransformativeMed, Inc. specializes in advanced clinical solutions aimed at glycemic management. Founded in 2011 and headquartered in Seattle, US, the company raised USD 5.8 mn in Series A funding in May 2019, led by Alliance of Angels. Erik Van Eaton is the founder, while David Stone and Doug Cusick currently serve as CEOs. There are no known pivots or changes in strategy since its inception.TransformativeMed specializes in providing cutting-edge clinical solutions with a focus on glycemic management through its flagship offering, the CORES Platform. This platform is designed by clinicians for clinicians and integrates seamlessly into Electronic Health Records (EHR) systems to enhance workflow efficiency and patient care quality. Key features of the CORES Platform include specialty-specific provider worklists, automated protocols for insulin dosing, real-time notifications, and comprehensive decision-support tools that streamline pre-rounding, rounding, and discharge planning processes. The company primarily serves hospitals and healthcare providers, enhancing the daily operations of clinical teams across various specialties, particularly in diabetes management. TransformativeMed's products are utilized in multiple geographical markets, including North America and select regions in Europe, where they address the need for effective glycemic control and improved patient outcomes.TransformativeMed generates revenue through a subscription-based model, wherein healthcare institutions pay for access to the CORES Platform and its suite of clinical solutions. Clients, which include hospitals and medical practices, often enter long-term partnerships that facilitate continuous integration and support of the platform within their existing EHR systems. The revenue structure typically involves tiered pricing plans based on the size of the institution and the specific modules utilized, allowing for customizable solutions that meet the diverse needs of various healthcare providers. By focusing on flagship services such as Core Diabetes and Core Work Manager, TransformativeMed ensures that its clients derive significant value from their investments, further solidifying long-term relationships within the healthcare sector.TransformativeMed plans to leverage the recent funding of USD 5.8 mn raised in May 2019 to support the development of new products designed to enhance their CORES Platform. The company aims to expand into additional markets across Europe by 2023, focusing on regions where diabetes management solutions are critically needed. This expansion will involve adapting the CORES Platform to meet specific regional healthcare needs, further solidifying TransformativeMed's position in the healthcare technology landscape.

## Funding rounds

- Series A, May 7, 2019, $5.8M — Alliance of Angels

## Investors

- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Series A